Key Takeaways One shot a month of an experimental drug yielded promising results in a new clinical trialThe drug, called ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

To get a sense of who is truly in control of Amgen Inc. (NASDAQ:AMGN), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company ...

Cantor Fitzgerald reaffirmed a neutral rating on Amgen, setting a $305 price target for the medical research firm. Despite ...

Retired pro football hall-of-famer Barry Sanders revealed he had a heart attack in 2024. But now he working to help other ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

In a statement on Monday, Amgen Inc. (NASDAQ:AMGN) announced that its phase 2 study of its weight loss drug candidate, ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Eagles tight end Dallas Goedert stops by to talk all things Eagles, another year of TEU and his partnership with Amgen.

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...